Colon cancer screening and surveillance

Research output: Contribution to journalArticle

Abstract

Colon cancer screening of average risk populations can reduce mortality from colorectal cancer (CRC), reduce cancer incidence, and has been shown to be cost-effective in the United States. The most effective screening test is uncertain. After patients are discovered to have neoplasia, colon surveillance is recommended. Surveillance is a costly part of colon screening programs, and the appropriate intervals for surveillance are uncertain. There is evidence that the majority of patients with adenomas could have extended intervals between surveillance exams, which would reduce cost and risk.

Original languageEnglish (US)
Pages (from-to)77-79
Number of pages3
JournalGastrointestinal Oncology
Volume4
Issue number2-3
DOIs
StatePublished - Jul 2002

Fingerprint

Early Detection of Cancer
Colonic Neoplasms
Colon
Costs and Cost Analysis
Adenoma
Colorectal Neoplasms
Neoplasms
Mortality
Incidence
Population

Keywords

  • Colorectal cancer
  • Screening
  • Sigmoidoscopy
  • Surveillance

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Colon cancer screening and surveillance. / Lieberman, David.

In: Gastrointestinal Oncology, Vol. 4, No. 2-3, 07.2002, p. 77-79.

Research output: Contribution to journalArticle

@article{b8b816245c9b4e70a4637baa36210298,
title = "Colon cancer screening and surveillance",
abstract = "Colon cancer screening of average risk populations can reduce mortality from colorectal cancer (CRC), reduce cancer incidence, and has been shown to be cost-effective in the United States. The most effective screening test is uncertain. After patients are discovered to have neoplasia, colon surveillance is recommended. Surveillance is a costly part of colon screening programs, and the appropriate intervals for surveillance are uncertain. There is evidence that the majority of patients with adenomas could have extended intervals between surveillance exams, which would reduce cost and risk.",
keywords = "Colorectal cancer, Screening, Sigmoidoscopy, Surveillance",
author = "David Lieberman",
year = "2002",
month = "7",
doi = "10.1080/1475956021000017002",
language = "English (US)",
volume = "4",
pages = "77--79",
journal = "Gastrointestinal Oncology",
issn = "1475-956X",
publisher = "Taylor and Francis Ltd.",
number = "2-3",

}

TY - JOUR

T1 - Colon cancer screening and surveillance

AU - Lieberman, David

PY - 2002/7

Y1 - 2002/7

N2 - Colon cancer screening of average risk populations can reduce mortality from colorectal cancer (CRC), reduce cancer incidence, and has been shown to be cost-effective in the United States. The most effective screening test is uncertain. After patients are discovered to have neoplasia, colon surveillance is recommended. Surveillance is a costly part of colon screening programs, and the appropriate intervals for surveillance are uncertain. There is evidence that the majority of patients with adenomas could have extended intervals between surveillance exams, which would reduce cost and risk.

AB - Colon cancer screening of average risk populations can reduce mortality from colorectal cancer (CRC), reduce cancer incidence, and has been shown to be cost-effective in the United States. The most effective screening test is uncertain. After patients are discovered to have neoplasia, colon surveillance is recommended. Surveillance is a costly part of colon screening programs, and the appropriate intervals for surveillance are uncertain. There is evidence that the majority of patients with adenomas could have extended intervals between surveillance exams, which would reduce cost and risk.

KW - Colorectal cancer

KW - Screening

KW - Sigmoidoscopy

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=0036664046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036664046&partnerID=8YFLogxK

U2 - 10.1080/1475956021000017002

DO - 10.1080/1475956021000017002

M3 - Article

VL - 4

SP - 77

EP - 79

JO - Gastrointestinal Oncology

JF - Gastrointestinal Oncology

SN - 1475-956X

IS - 2-3

ER -